Company Analysis
Sign in

BeyondSpring Inc. (BYSI)

Nasdaq: BYSI · Pharmaceutical Preparations · Florham Park, NJ · filing with the SEC since 2016
Full chart Alerts Compare
Grade4.8
◀ Past 3.8● Present 4.9▶ Future 5.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

21 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BeyondSpring Inc.’s names, not what it holds today.

Patents granted
21
21 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 2 in 2023
Applications published
35
5 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'13'16'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals12
Chemical engineering2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
BeyondSpring Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
33 published
BeyondSpring Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent
21 granted
1 published
Seed Therapeutics US, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
1 published
Names not counted (2)
BeyondSpring Inc.
Most of its patents print KY; this name counts in US. 1 granted and 0 published under it are not counted.
BeyondSpring Inc.
Most of its patents print KY; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Nov 4, 202512,458,639Tubulin binding compounds and therapeutic use thereofPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Nov 4, 202512,458,638Method of stimulating neutrophil survival and reducing neutropeniaPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Oct 7, 202512,433,886Composition and method for reducing neutropeniaPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Aug 5, 202512,377,094Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapiesPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Jul 2, 202412,024,501Plinabulin compositionsChemical engineeringBeyondSpring Pharmaceuticals, Inc.
Mar 5, 202411,918,574Method of treating cancer associated with a RAS mutationPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Jan 2, 202411,857,522Compositions containing tucaresol or its analogsPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Oct 17, 202311,786,523Composition and method for reducing thrombocytopeniaPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Apr 25, 202311,633,393Tubulin binding compounds and therapeutic use thereofPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Aug 2, 202211,400,086Method of reducing chemotherapy-induced neutropeniaPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0375440COMPOSITION AND METHOD OF TREATING CANCER ASSOCIATED WITH EGFR MUTATIONPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Nov 27, 20252025/0362302INTRACELLULAR LIGATION OF PHOTOCATALYSTS FOR PHOTO-RESPONSIVE, PROBE-MEDIATED PROTEIN LABELINGAnalysis of biological materialsSeed Therapeutics US, Inc.
May 15, 20252025/0152473STABLE PLINABULIN FORMULATIONS AND METHODS OF THEIR PREPARATION AND USEPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Mar 6, 20252025/0073231THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORSPharmaceuticalsBeyondSpring Pharmaceuticals, Inc. · patent 12,377,094 granted from it
Mar 6, 20252025/0073230USE OF PLINABULIN IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORSPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Dec 26, 20242024/0425485PLINABULIN COMPOSITIONSChemical engineeringBeyondSpring Pharmaceuticals, Inc.
Dec 12, 20242024/0408082METHODS FOR TREATING CANCERS AND TUMORSPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Nov 7, 20242024/0368126IMPURITY IN PLINABULIN OR PREPARATION THEREOF, AND USE THEREOFPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Sep 12, 20242024/0299377METHODS AND COMPOSITIONS FOR TREATING IRON DISORDERSPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
Jun 20, 20242024/0197723THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING TUMORSPharmaceuticalsBeyondSpring Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Chemical engineering 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BYSI · research, not advice